CORT003 (diagnostic test)

Cortendo Invest AB owns the rights to a novel diagnostic test for cortisol hyperactivity, designed to enable the early detection of Metabolic Syndrome before the development of overt symptoms. The company believes that it is an important competitive advantage to be able to identify the patients on a very early stage.